Qualigen Therapeutics Announces Change of Control and Executive Changes
Ticker: AIXC · Form: 8-K · Filed: Jul 11, 2024 · CIK: 1460702
Sentiment: mixed
Topics: change-of-control, executive-changes, definitive-agreement
TL;DR
Qualigen's changing hands, new execs in, old ones out. Big shakeup!
AI Summary
On July 5, 2024, Qualigen Therapeutics, Inc. entered into a material definitive agreement related to a change in control of the company. The filing also announced the departure of certain officers and directors, along with the appointment of new officers and directors, and details compensatory arrangements. Additionally, the company reported on other events and filed financial statements and exhibits.
Why It Matters
This filing indicates a significant shift in the company's leadership and ownership structure, which could impact its strategic direction and future performance.
Risk Assessment
Risk Level: medium — Changes in control and executive departures often signal significant strategic shifts or underlying issues that can introduce uncertainty and risk.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- July 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- RITTER PHARMACEUTICALS INC (company) — Former company name
- 20090402 (date) — Date of former company name change
FAQ
What is the nature of the material definitive agreement entered into by Qualigen Therapeutics?
The filing indicates a material definitive agreement related to a change in control of the registrant.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on July 5, 2024.
What specific items are covered under the 'Changes in Control of Registrant' section?
The filing mentions a change in control of the registrant as an item of information.
Besides changes in control, what other personnel-related events are reported?
The filing reports the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What was Qualigen Therapeutics, Inc.'s former company name?
Qualigen Therapeutics, Inc.'s former company name was RITTER PHARMACEUTICALS INC.
Filing Stats: 756 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2024-07-11 17:25:27
Key Financial Figures
- $2,000,000 — d terms, against the investor's loan of $2,000,000 in cash: (a) an original principal amou
- $3,300,000 — ch had an original principal balance of $3,300,000) into Company common stock; as a result
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex10-1.htm (EX-10.1) — 239KB
- 0001493152-24-027015.txt ( ) — 504KB
- qlgn-20240705.xsd (EX-101.SCH) — 3KB
- qlgn-20240705_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240705_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: July 11, 2024 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer